ID   KAT-4
AC   CVCL_6304
SY   KAT 4; KAT4
DR   BioSample; SAMN03151790
DR   cancercelllines; CVCL_6304
DR   ChEMBL-Cells; CHEMBL3307845
DR   ChEMBL-Targets; CHEMBL614008
DR   Cosmic; 886548
DR   Cosmic; 891253
DR   Cosmic; 1068626
DR   Cosmic; 1162839
DR   Cosmic; 2050372
DR   IARC_TP53; 21624
DR   PubChem_Cell_line; CVCL_6304
DR   Wikidata; Q54899532
RX   PubMed=12481943;
RX   PubMed=14522906;
RX   PubMed=17465858;
RX   PubMed=17804723;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland anaplastic carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00222.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=14522906).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): PubMed=17465858; PubMed=18713817; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11 (PubMed=17465858; PubMed=18713817)
ST   D13S317: 11,13 (PubMed=21868764)
ST   D16S539: 9,11,12
ST   D18S51: 13
ST   D21S11: 30
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 8,10,12 (PubMed=21868764)
ST   D7S820: 10 (PubMed=17465858; PubMed=18713817)
ST   D8S1179: 10 (PubMed=17465858)
ST   D8S1179: 10,16 (PubMed=18713817)
ST   FGA: 20,22
ST   TH01: 6,7
ST   TPOX: 8,9,11
ST   vWA: 16,17,18,19 (PubMed=21868764)
ST   vWA: 17,19 (PubMed=17465858; PubMed=18713817)
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 32
//
RX   PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026;
RA   van Staveren, Wilma C.G.
RA   Weiss-Solis, David Y.
RA   Delys, Laurent
RA   Duprez, Laurence
RA   Andry, Guy
RA   Franc, Brigitte
RA   Thomas, Gerry
RA   Libert, Frederick
RA   Dumont, Jacques-Emile
RA   Detours, Vincent
RA   Maenhaut, Carine
RT   "Human thyroid tumor cell lines derived from different tumor types
RT   present a common dedifferentiated phenotype.";
RL   Cancer Res. 67:8113-8120(2007).
//
RX   PubMed=12481943; DOI=10.1089/105072502760339343;
RA   Husmark, Johanna
RA   Heldin, Nils-Erik
RA   Nilsson, Mikael
RT   "Follicular growth of a thyroid carcinoma cell line (KAT-4) with
RT   abnormal E-cadherin and impaired epithelial barrier.";
RL   Thyroid 12:781-790(2002).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662;
RA   Zhao, Mei
RA   Sano, Daisuke
RA   Pickering, Curtis R.
RA   Jasser, Samar A.
RA   Henderson, Ying C.
RA   Clayman, Gary L.
RA   Sturgis, Erich M.
RA   Ow, Thomas J.
RA   Lotan, Reuben
RA   Carey, Thomas E.
RA   Sacks, Peter G.
RA   Grandis, Jennifer Rubin
RA   Sidransky, David
RA   Heldin, Nils-Erik
RA   Myers, Jeffrey N.
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe, Rebecca E.
RA   Klopper, Joshua Paul
RA   Korch, Christopher T.
RA   Pugazhenthi, Umarani
RA   Benezra, Miriam
RA   Knauf, Jeffrey A.
RA   Fagin, James Alexander
RA   Marlow, Laura A.
RA   Copland, John Alton 3rd
RA   Smallridge, Robert Christian
RA   Haugen, Bryan R.
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis, Amanda
RA   Theodosopoulos, George
RA   Atkin, Isobel
RA   Drexler, Hans Gunther
RA   Kohara, Arihiro
RA   MacLeod, Roderick A.F.
RA   Masters, John R.W.
RA   Nakamura, Yukio
RA   Reid, Yvonne A.
RA   Reddel, Roger Robert
RA   Freshney, Robert Ian
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=17465858; DOI=10.1089/thy.2006.0246;
RA   Lee, Jia-Jing
RA   Foukakis, Theodoros
RA   Hashemi, Jamileh
RA   Grimelius, Lars
RA   Heldin, Nils-Erik
RA   Wallin, Goran
RA   Rudduck, Christina
RA   Lui, Weng-Onn
RA   Hoog, Anders
RA   Larsson, Catharina
RT   "Molecular cytogenetic profiles of novel and established human
RT   anaplastic thyroid carcinoma models.";
RL   Thyroid 17:289-301(2007).
//
RX   PubMed=14522906;
RA   Frasca, Francesco
RA   Vella, Veronica
RA   Aloisi, Alessandra
RA   Mandarino, Angelo
RA   Mazzon, Emanuela
RA   Vigneri, Riccardo
RA   Vigneri, Paolo
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
//